Market capitalization | $325.04m |
Enterprise Value | $194.16m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 46.12 |
P/S ratio (TTM) P/S ratio | 77.21 |
P/B ratio (TTM) P/B ratio | 1.61 |
Revenue growth (TTM) Revenue growth | -39.35% |
Revenue (TTM) Revenue | $4.21m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Absci Corp forecast:
7 Analysts have issued a Absci Corp forecast:
Sep '24 |
+/-
%
|
||
Revenue | 4.21 4.21 |
39%
39%
|
|
Gross Profit | -9.43 -9.43 |
32%
32%
|
|
EBITDA | -90 -90 |
17%
17%
|
EBIT (Operating Income) EBIT | -103 -103 |
14%
14%
|
Net Profit | -98 -98 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AbSci Corp. engages in the development of protein biomanufacturing technology. It offers SoluPro, an all-in-one protein expression platform which produces complex proteins using simplest and least expensive organism. The company was founded by Sean Mcclain and Mark Valasek in 2011 and is headquartered in Vancouver, WA.
Head office | United States |
CEO | Sean McClain |
Employees | 156 |
Founded | 2011 |
Website | www.absci.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.